Last reviewed · How we verify
GSK573719 125
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | GSK573719 125 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
GSK573719 is an inhaled anticholinergic agent that selectively antagonizes muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-mediated bronchoconstriction. This results in sustained airway relaxation and improved lung function. The drug is formulated as a once-daily maintenance therapy for chronic obstructive pulmonary disease (COPD).
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Dry mouth
- Tremor
- Headache
- Nasopharyngitis
Key clinical trials
- A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (PHASE3)
- A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (PHASE3)
- Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks (PHASE3)
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
- A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component (PHASE2)
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719 125 CI brief — competitive landscape report
- GSK573719 125 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI